AZD1897
Product Specifications
UNSPSC Description
AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib (HY-15431). This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways[1][2].
Target Antigen
Pim
Type
Reference compound
Related Pathways
JAK/STAT Signaling
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/azd1897.html
Solubility
DMSO : 20 mg/mL (ultrasonic;warming;adjust pH to 2 with 1 M HCL;heat to 60°C)
Smiles
O=C(NC/1=O)SC1=C/C2=CC=CC(OC(C)C)=C2N3C[C@H](N)CCC3
Molecular Weight
361.46
References & Citations
[1]Dakin LA, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4599-604. |[2]Meja K, et al. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. Br J Haematol. 2014 Oct;167(1):69-79.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-164460/AZD1897-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-164460/AZD1897-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
1204181-93-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
